Karen Krasney Buys Shares of Capricor Therapeutics
Karen Krasney, EVP, acquired 400 shares of Capricor Therapeutics at $3.18 each.
Key Points
- Karen Krasney, EVP of Capricor Therapeutics, purchased 400 shares at $3.18 each on June 24, 2026.
- Capricor Therapeutics, trading on NasdaqGS under CAPR, has a market cap of $1.7 billion, with a 52-week high of $40.37.
- Analysts from B. Riley Securities and Piper Sandler maintain a 'buy' rating with price targets of up to $63.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Karen Krasney, Executive Vice President and General Counsel at Capricor Therapeutics, Inc. (NasdaqGS: CAPR), made a notable move by purchasing 400 shares of the company on June 24, 2026. The shares were bought at an average price of $3.18, amounting to a total transaction value of approximately $1,272. This insider transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Capricor Therapeutics, Inc.
In addition to Karen Krasney's purchase, other insider transactions occurred on the same day. Anthony Bergmann, the Chief Financial Officer, also bought 400 shares at $3.18 each. However, both Krasney and Bergmann sold 400 shares at a price of $30.00 each. These transactions were also not part of any pre-arranged plans.
Capricor Therapeutics, Inc. Stock Up 207.7%
Shares of Capricor Therapeutics, Inc. traded near $29.60 on Thursday. The company, which operates in the biotechnology sector, has a market capitalization of approximately $1.7 billion. It currently has no meaningful P/E ratio as it isn't profitable, and its beta is relatively low at 0.368, indicating lower volatility compared to the market. The stock's 52-week range is between $4.30 and $40.37, with a 50-day moving average of $30.58 and a 200-day moving average of $21.38. Capricor maintains a strong liquidity position with a current ratio of 8.416 and a quick ratio of 8.283.
$CAPR stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On March 13, 2026, B. Riley Securities maintained its 'buy' rating on Capricor Therapeutics, setting a price target of $63.00. Piper Sandler also reiterated its 'buy' rating with a target price of $58.00. Overall, the consensus among nine analysts is a 'strong buy', with an average target price of $54.11.
About Capricor Therapeutics
Capricor Therapeutics, Inc., based in San Diego, California, is a clinical-stage biotechnology company. It focuses on developing transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy and other diseases with unmet medical needs. The company's lead product candidate, Deramiocel, is in phase 3 clinical trials for Duchenne muscular dystrophy. Capricor also works on various exosome-based platforms for therapeutic development. Dr. Linda Marbán serves as the CEO, and the company employs around 231 people.
Bottom Line
Karen Krasney's recent purchase of Capricor Therapeutics shares highlights insider confidence in the company's prospects. Investors often track such insider activity as it can provide insights into the company's future performance. However, it's important to remember that these insights are based on past filings and may not reflect current positions.
Get Capricor Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CAPR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.